Research & Development at Nielsen Biosciences
The active ingredient in our CANDIN product, currently approved for the assessment of cellular hypersensitivity to Candida albicans, is currently under investigation for the treatment of Verruca vulgaris or common warts. CANDIN is not currently approved for the treatment of common warts, but we are exploring whether this biologic product may provide an opportunity to leverage the body’s immune response to more effectively address that condition. Nielsen BioSciences has completed a Phase 2 clinical trial, and we are currently evaluating the next steps in clinical development for this indication.
This program is investigational, CANDIN is not currently approved for the treatment of common warts.
Leishmania Skin Test Antigen is made from the promastigote form of the parasite Leishmania. Phase 2 studies have been completed. Parasites of the genus Leishmania are found worldwide and cause the diseases of cutaneous or visceral leishmaniasis. The World Health Organization estimates there are 12 million cases of leishmaniasis from a population of 350 million at-risk individuals.
Information on our ongoing clinical trials can be seen at ClinicalTrials.gov/NCT02393417